8-K: Cross Country Healthcare Reports Q4, Full Year 2025 Losses

Cross Country Healthcare, Inc. announced significant net losses for the fourth quarter and full year ended December 31, 2025, alongside revenue declines, despite positive cash flow and a strong balance sheet.

Summary

• Consolidated revenue for Q4 2025 was $236.8 million, a 24% decrease year-over-year and 5% sequentially.
• Full year 2025 consolidated revenue was $1.05 billion, a 22% decrease year-over-year.
• Net loss attributable to common stockholders was $(82.9) million in Q4 2025, compared to a net loss of $(3.8) million in Q4 2024.
• Full year 2025 net loss attributable to common stockholders was $(94.9) million, compared to a net loss of $(14.6) million in full year 2024.
• Diluted EPS was a net loss of $(2.56) in Q4 2025 and $(2.93) for the full year 2025.
• Adjusted EBITDA was $4.1 million in Q4 2025 (down 56% year-over-year) and $26.8 million for the full year 2025 (down 45% year-over-year).
• The net loss was primarily driven by a $77.9 million goodwill and trade name impairment charge and a $29.6 million valuation allowance against deferred tax assets.
• The company received a $20.0 million termination fee in Q4 2025 related to the terminated Aya Merger Agreement.
• Repurchased over 800,000 shares, or 2.5% of common stock outstanding, for $6.5 million in Q4 2025.
• Reduced US headcount by 21% in 2025, contributing to cost savings.
• Maintained a strong balance sheet with $108.7 million of cash on hand and no debt as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to substantial net losses, significant revenue and EBITDA declines, and large impairment charges, despite some positive operational highlights and a strong balance sheet.

Positives

• Continued positive cash flow from operations, with $18.2 million in Q4 2025 and $48.3 million for the full year 2025.
• Strong balance sheet with $108.7 million of cash on hand and no debt as of December 31, 2025.
• Repurchased over 800,000 shares, representing 2.5% of common stock outstanding, for $6.5 million in the fourth quarter.
• Reduced US headcount by 21% in 2025, driving cost savings through the India center of excellence.
• Received a $20.0 million termination fee from the Aya Merger Agreement during the fourth quarter.
• 95% of MSP and vendor neutral clients are now live on Intellify, the company's proprietary technology.

Negatives

• Reported a significant net loss attributable to common stockholders of $(82.9) million in Q4 2025 and $(94.9) million for the full year 2025.
• Diluted EPS was a net loss of $(2.56) in Q4 2025 and $(2.93) for the full year 2025.
• Consolidated revenue decreased 24% year-over-year in Q4 2025 and 22% for the full year 2025.
• Adjusted EBITDA decreased 56% year-over-year in Q4 2025 to $4.1 million and 45% for the full year 2025 to $26.8 million.
• Incurred a substantial goodwill and trade name impairment charge of $77.9 million in Q4 2025.
• Recorded a $29.6 million valuation allowance against deferred tax assets.
• Nurse and Allied Staffing revenue decreased 24% year-over-year in Q4 2025.
• Physician Staffing revenue decreased 20% year-over-year in Q4 2025.
• Net cash provided by operating activities for the full year 2025 decreased 60% year-over-year to $48.3 million.

Risks

• Worldwide economic or political changes that affect the markets served, impacting demand for services and profitability.
• Effects from global pandemics, epidemics, or other public health crises.
• Changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, and customer needs.
• Disruptions in global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, foreign currency volatility, swings in consumer confidence and spending, and the overall macroeconomic environment.
• The functioning of information systems and the effect of cybersecurity risks and cyber incidents on the business.
• Demand for the healthcare services provided, both nationally and in the regions of operation.
• Leadership transitions and retention of key employees.
• Ability to attract and retain qualified nurses, physicians, and other healthcare personnel.
• Costs and availability of short-term housing for travel healthcare professionals.
• The effect of existing or future government regulation and federal and state legislative and enforcement initiatives on the business.
• Outcomes of regulatory and legal proceedings, claims, and investigations.

Future Outlook

For the first quarter of 2026, the company expects revenue between $235 million and $240 million, Adjusted EBITDA between $4.0 million and $5.0 million, and Adjusted EPS between $(0.06) and $(0.04). The CEO is encouraged by signs of an improving market and expects sequential progression throughout 2026, with a goal to exit the year at a revenue run-rate north of $1 billion and a profit margin between four and five percent.

Management Comments

• "In addition to a challenging market backdrop, particularly for travel staffing, our performance last year was certainly impacted by the protracted merger process." Kevin C. Clark, Co-Founder, Chairman, and CEO.
• "As we enter 2026 unencumbered and laser focused, I’m encouraged, not just by the signs of an improving market, but also by the returns from the investments and actions we have taken already." Kevin C. Clark, Co-Founder, Chairman, and CEO.
• "The engine of our growth is centered around our proprietary technology Intellify and along with strategic investments in revenue producers and the leverage of our robust balance sheet, I believe we will see sequential progression throughout 2026." Kevin C. Clark, Co-Founder, Chairman, and CEO.
• "Our goal is to exit the year at a revenue run-rate north of $1 billion and a profit margin between four and five percent." Kevin C. Clark, Co-Founder, Chairman, and CEO.

Industry Context

StockSavvy.ai notes that the company's performance was significantly impacted by a challenging market backdrop, particularly for travel staffing, which aligns with broader industry trends of normalizing demand for temporary healthcare professionals post-pandemic surges. The focus on proprietary technology like Intellify and cost savings through headcount reduction reflects a strategic pivot common among healthcare staffing firms adapting to a more competitive and cost-conscious environment.

Management Changes

Legal Proceedings

• The company incurred legal costs and other settlement charges as presented on the consolidated statements of operations.
• The company incurred losses pertaining to matters outside the normal course of operations.
• A settlement expense of $1.2 million was incurred, and a $1.8 million recovery related to a previous loss was recorded in Q4 2024.
• Risks include outcomes of regulatory and legal proceedings, claims, and investigations.

Stakeholder Impact

• Shareholders: Significant net losses and diluted EPS decline negatively impact shareholder value, though share repurchases offer some mitigation.
• Employees: US headcount was reduced by 21% in 2025, indicating job losses as part of cost-saving initiatives.
• Customers: Continued adoption of Intellify, with 95% of MSP and vendor neutral clients now live, suggests ongoing engagement with the technology platform.
• Creditors: A strong balance sheet with $108.7 million in cash and no outstanding debt indicates low credit risk.

Next Steps

• Hold a quarterly conference call on March 4, 2026, at 5:00 P.M. Eastern Time to discuss financial results.
• Aim to exit 2026 at a revenue run-rate north of $1 billion.
• Target a profit margin between four and five percent by the end of 2026.
• Continue strategic investments in revenue producers and leverage the robust balance sheet.
• Focus on sequential progression throughout 2026.

Key Dates

Recommendation

The company reported substantial net losses and significant year-over-year declines in revenue and Adjusted EBITDA, driven by a challenging market and a large goodwill impairment charge. While the balance sheet is strong and cost-saving measures are in place, the magnitude of the losses and the negative outlook for Q1 2026 suggest continued headwinds. The termination of the merger agreement and the associated impairment indicate strategic challenges. Investors should consider selling given the poor financial performance and uncertain near-term recovery.

Keywords

Healthcare Staffing, Nurse Staffing, Physician Staffing, Travel Nursing, Workforce Solutions, Healthcare Technology, Intellify, CCRN, Financial Results, Earnings Report, SEC Filing, Goodwill Impairment, Share Repurchase, Cost Savings